| Stereochemistry | ABSOLUTE |
| Molecular Formula | C27H49N5O8 |
| Molecular Weight | 571.7067 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCCCCCCC(=O)N[C@@H](C)C(=O)N[C@H](CCC(=O)N[C@@H](CCC[C@H](N)C(N)=O)C(O)=O)C(O)=O
InChI
InChIKey=TUNXCNXMSJZNPO-XSDIEEQYSA-N
InChI=1S/C27H49N5O8/c1-3-4-5-6-7-8-9-10-11-15-22(33)30-18(2)25(36)32-21(27(39)40)16-17-23(34)31-20(26(37)38)14-12-13-19(28)24(29)35/h18-21H,3-17,28H2,1-2H3,(H2,29,35)(H,30,33)(H,31,34)(H,32,36)(H,37,38)(H,39,40)/t18-,19-,20-,21+/m0/s1
Tabilautide (also known as RP 56142) is a tripeptide derivative patented by Rhone-Poulenc Industries S. A. as an immune adjuvant. In preclinical studies, Tabilautide displays potent protective activities against bacterial infections such as K. pneumoniae, L. monocytogenes or S. Typhimurium. Besides that Tabilautide shows antimetastatic activity and induces macrophage activation and enhanced cytotoxicity of natural killer cells in spleen, blood, and liver. These activities correlate with prophylactic and therapeutic effects of Tabilautide on artificial liver metastases of histiocytosarcoma.
Originator
Approval Year
PubMed
Patents
ACTIVE MOIETY
